Imugene Limited Stock Performance
| IUGNF Stock | USD 0.18 0.02 10.00% |
On a scale of 0 to 100, Imugene holds a performance score of 2. The company retains a Market Volatility (i.e., Beta) of 2.64, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Imugene will likely underperform. Please check Imugene's value at risk, as well as the relationship between the expected short fall and day median price , to make a quick decision on whether Imugene's current trending patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Imugene Limited are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Imugene reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 29.5 M | |
| Total Cashflows From Investing Activities | -221 K |
Imugene |
Imugene Relative Risk vs. Return Landscape
If you would invest 20.00 in Imugene Limited on November 19, 2025 and sell it today you would lose (2.00) from holding Imugene Limited or give up 10.0% of portfolio value over 90 days. Imugene Limited is currently producing 0.2809% returns and takes up 9.9383% volatility of returns over 90 trading days. Put another way, 89% of traded pink sheets are less volatile than Imugene, and 95% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Imugene Target Price Odds to finish over Current Price
The tendency of Imugene Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.18 | 90 days | 0.18 | over 95.15 |
Based on a normal probability distribution, the odds of Imugene to move above the current price in 90 days from now is over 95.15 (This Imugene Limited probability density function shows the probability of Imugene Pink Sheet to fall within a particular range of prices over 90 days) .
Imugene Price Density |
| Price |
Predictive Modules for Imugene
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Imugene Limited. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Imugene Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Imugene is not an exception. The market had few large corrections towards the Imugene's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Imugene Limited, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Imugene within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.05 | |
β | Beta against Dow Jones | 2.64 | |
σ | Overall volatility | 0.02 | |
Ir | Information ratio | 0 |
Imugene Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Imugene for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Imugene Limited can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Imugene Limited had very high historical volatility over the last 90 days | |
| Imugene Limited has some characteristics of a very speculative penny stock | |
| Imugene Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M. | |
| Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 15.0% of the company shares are held by company insiders |
Imugene Fundamentals Growth
Imugene Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Imugene, and Imugene fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Imugene Pink Sheet performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.21 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 737.79 M | |||
| Shares Outstanding | 6.42 B | |||
| Price To Book | 8.51 X | |||
| Price To Sales | 61.84 X | |||
| Revenue | 12.97 M | |||
| EBITDA | (37.56 M) | |||
| Cash And Equivalents | 99.89 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 673.43 K | |||
| Debt To Equity | 0 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (30.85 M) | |||
| Earnings Per Share | (0) X | |||
| Total Asset | 147.61 M | |||
About Imugene Performance
By analyzing Imugene's fundamental ratios, stakeholders can gain valuable insights into Imugene's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Imugene has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Imugene has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Imugene is traded on OTC Exchange in the United States.Things to note about Imugene Limited performance evaluation
Checking the ongoing alerts about Imugene for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Imugene Limited help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Imugene Limited had very high historical volatility over the last 90 days | |
| Imugene Limited has some characteristics of a very speculative penny stock | |
| Imugene Limited has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.97 M. Net Loss for the year was (37.87 M) with profit before overhead, payroll, taxes, and interest of 12.97 M. | |
| Imugene Limited has accumulated about 99.89 M in cash with (30.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02. | |
| Roughly 15.0% of the company shares are held by company insiders |
- Analyzing Imugene's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Imugene's stock is overvalued or undervalued compared to its peers.
- Examining Imugene's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Imugene's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Imugene's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Imugene's pink sheet. These opinions can provide insight into Imugene's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Imugene Pink Sheet analysis
When running Imugene's price analysis, check to measure Imugene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imugene is operating at the current time. Most of Imugene's value examination focuses on studying past and present price action to predict the probability of Imugene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imugene's price. Additionally, you may evaluate how the addition of Imugene to your portfolios can decrease your overall portfolio volatility.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |